Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion (NCT05807984) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion
China31 participantsStarted 2023-05-01
Plain-language summary
Prospective phase II clinical study aim to explore the clinical outcome of patients with unresectable locally recurrent rectal cancer (LRRC) treated with re-irradiation by carbon ion radiotherapy (CIRT)
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\) pathologically confirmed rectal adenocarcinoma (including mucinous adenocarcinoma and signet-ring cell carcinoma) and LRRC confirmed by biopsy or clinical diagnosis,
* 2\) received a radical operation for their primary tumor and regional lymph nodes,
* 3\) received chemo-radiation or radiation in pelvic before CIRT,
* 4\) received re-irradiation by CIRT after their pelvic radiotherapy.
Exclusion Criteria:
* 1\) received more than once prior radiotherapy in the same treatment field,
* 2\) time to the last radiotherapy was \<1 year,
* 3\) space between the lesion to organ at risk (OARs) (bladder or digestive tract) was too close (\<5 mm).